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1. INTRODUCTION 
The International Association for the Study of Pain (IASP), 2011 states that pain is an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or described 
in terms of such damage. Epidemiological survey reported that chronic neuropathic pain greatly 
affects physical and mental health as well as the social and daily lives of those with this 
condition. It significantly reduced the quality of life and imposed economic burdens on 
individuals and society (Inoue S et al., 2017). The estimate of prevalence of pain with 
neuropathic characteristic probably varies between 6.9 and 10%. Broadly pain is classified into 
three types nociceptive pain, (caused by the stimulation of peripheral A-delta and C- polymodal 
pain receptors and by algogenic substances such as histamine, bradykinin, substance P) 
inflammatory pain (associated with tissue damage and infiltration of immune cells) and 
neuropathic pain (Manoj et al. ,2016).   
 Nociceptive pain: Represents the normal response to noxious insult or injury of tissue 
such as skin, muscles, visceral organs, joints, tendons or bones. 
 Neuropathic pain: Pain initiated or caused by a primary lesion or disease in the 
somatosensory nervous system. 
 Inflammatory pain: It occurs as a resultof activation and sensitization of the nociceptive 
pain pathway by a variety of mediators released at a site of tissue inflammation.  
In general pain is classified into acute and chronic pain depending on the duration. 
o Acute pain: pain of less than 3 to 6 months duration. 
o Chronic pain: pain lasting for more than 3-6 months, or persisting beyond the course 
of an acute disease, or after tissue healing is complete.  
The general causes of pain include muscle spasms, increased central sensitization to pain, 
pathological sensitization, vitamin D deficiency ,drug side effects (especially bisphosphonates 
and statins), analgesic rebound.  
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1.1.PATHOPHYSIOLOGY OF PAIN 
 
Fig: 1. Pathophysiology of pain 
It involves the following processes: 
a) Transduction: 
Pain stimulus is converted into electrical energy. This electrical energy is known as 
Transduction. This stimulus sends an impulse across a peripheral nerve fiber (nociceptor). 
b) Transmission: 
A  fibers (myelinated) send sharp, localized and distinct sensations and C fibers (unmyelinated) 
relay impulses that are poorly localized, burning and persistent pain. Pain stimulus is then 
travelled to the spinothalamic tract. 
c) Modulation: 
Inhibitory neurotransmitters like endogenous opioids hinder the pain transmission. This 
inhibition of the pain impulse is known as modulation. 
d) Perception:   
In thisperson is aware of pain and unfolds a complex reaction and the somatosensory cortex 
identifies the location and intensity of pain. (Physiological and behavioral responses is 
perceived). 
e) Interpretation and pain response 
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Neuropathic pain as defined by The International Association for the Study of Pain is ―pain 
initiated or caused by a primary lesion in the nervous system‖ (Jaggi et al., 2014).Neuropathic 
pain is a type of chronic pain which is caused by lesion or disease of the somatosensory system, 
including peripheral fibres (Aβ, Aδ and C fibres) and central neurons and affects 7–10% of the 
general population. The somato-sensory system allows for the perception of touch, pressure, 
pain, temperature, position, movement and vibration. The somatosensory nerves arise in the skin, 
muscles, joints and fascia and they include thermoreceptors, mechanoreceptors, chemoreceptors, 
pruriceptors and nociceptors that send signals to the spinal cord and eventually to the brain for 
further processing (Abbott CA et al., 2011). Most sensory processes involve a thalamic nucleus 
receiving a sensory signal that is then directed to the cerebral cortex. Lesions or diseases of the 
somatosensory nervous system can lead to altered and disordered transmission of sensory signals 
into the spinal cord and the brain (Colloca et al., 2017). Imbalances between excitatory 
and inhibitory somatosensory signalling, alterations in ion channels and variability in the way 
that pain messages are modulated in the central nervous system all have been implicated in 
neuropathic pain.  
Neuropathic pain may result from disorders of the peripheral nervous system or the central 
nervous system (brain and spinal cord). Thus, neuropathic pain may be divided into peripheral 
neuropathic pain (nerves of peripheral nervous sytem are damaged), central neuropathic pain 
(nerves of central nervous system are damaged) or mixed (peripheral and central) neuropathic 
pain. Peripheral neuropathic pain is caused due to certain conditions such as painful diabetic 
neuralgia, trigeminal neuralgia, lumbar radiculopathy, nerve damage, pain because of cancer 
tumor infiltration, alcohol neuropathy. Central neuropathic pain is caused due to several factors 
such as Post-stroke pain, multiple sclerosis, chemotherapy-induced pain. 
1.2.ETIOLOGY 
Neuropathic pain is caused by several factors such as: 
 Diabetes: It is one of the conditions which is most commonly associated with neuropathy. The 
characteristic symptoms of peripheral neuropathy often seen in diabetic people known as diabetic 
neuropathy.  
 Vitamin deficiencies: Deficiencies of the vitamins B12 and folate as well as other vitamins can 
cause damage to the nerves. 
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 Autoimmune neuropathy: Autoimmune diseases such as rheumatoid arthritis, systemic lupus 
and Guillain-Barre syndrome can cause neuropathies. 
 Infection: Some infections, including HIV/AIDS, Lyme disease, leprosy, and syphilis can 
damage nerves. 
 Post-herpetic neuralgia: Post-herpetic neuralgia, a complication of shingles (varicella-zoster 
virus infection) is a form of neuropathy. 
 Alcoholic neuropathy: Alcoholism is often associated with peripheral neuropathy. Although the 
exact reasons for the nerve damage are unclear, it probably arises from a combination of damage 
to the nerves by alcohol itself along with the poor nutrition and associated vitamin deficiencies 
that are common in alcoholics. 
 Genetic or inherited disorders: Genetic or inherited disorders can affect the nerves and are 
responsible for some cases of neuropathy disease. 
In general neuropathic pain occurs as a result of the increased neuronal expression and/or 
activation of ion channels and receptors operating at the peripheral, spinal cord and supra-spinal 
levels, which causes alterations in the pain conduction pathway. This may also develop 
secondary to some  pathological conditions like  diabetes mellitus, cancer, herpes infection, 
autoimmune diseases and HIV infection   (Jaggi et al., 2014). 
Neuropathic pain could be a blend of many sensory indications such as paresthesias (numbness 
or tingling), dysesthesias (electric shock phenomenon), hyperesthesia (increased sensitivity to 
mild painful stimuli), hyperalgesia (increased sensitivity to normally painful stimuli), 
hyperpathia (pain produced by subthreshold stimuli), spontaneous pain and allodynia (pain 
produced by normally non painful stimuli (Nischaltyagi et al., 2014. Sensations of burning pain 
may be occur due to the  continuous discharge in C-fibers, whereas  dysesthesias  (unpleasant 
abnormal sensations) and  paresthesias  (abnormal sensations) may arise from intermittent 
spontaneous discharges in A-  or A- β fibers (Meena S et al., 2011). Peripheral sensitization 
mediated through C-fiber primary afferent neurons, may be the mechanism responsible for 
hyperalgesia. Two types of hyperalgesia are frequently described a) Primary hyperalgesia, which 
is increased pain and sensitivity at the site of injury.  It is caused due to the peripheral changes 
that occur after tissue damage.b) Secondary hyperalgesia, which is increased sensitivity and pain 
in uninjured tissue that surrounds the site of injury. It results from the events that occur within 
the dorsal horn of the spinal cord after injury.  
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Allodynia is mediated by Aβ fibres .It is caused due to the central changes that occur after tissue 
damage. 
 
1.3.PATHOGENESIS OF NEUROPATHIC PAIN 
  
 
Fig: 2. Pathogenesis of neuropathic pain 
1.3.1. PERIPHERAL MECHANISMS OF NEUROPATHIC PAIN  
Neuropathic pain in the peripheral nervous system may occur due to the following reasons: 
1. Ectopic discharges in lesioned ﬁbers and their corresponding ganglia  
2. Abnormal activity in axons undamaged by the lesion  
3. Alterations in the expression and regulation of intracellular Ca
2+
 ion and modulatory receptors 
on primary afferent terminals  
4. Neuroimmune interactions resulting in enhanced and/or altered production of inﬂammatory 
signaling molecules 
5. Sensory-sympathetic coupling and other alterations in receptor signaling 
1. Ectopic discharges in injured fibres 
After an injury in the peripheral nervous system, chemicals such as noradrenaline, bradykinin, 
histamine, prostaglandins, potassium, cytokines, 5HT, and neuropeptides are released from 
damaged cells and inflammatory cells (e.g., mast cells, lymphocytes).These cellular mediators 
act to sensitize nociceptors to further neural input.This produces changes in the number and 
location of ion channels especially sodium ion channels in the injured nociceptor nerve fibers 
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and their dorsal root ganglia (Campero M et al., 1998). As a result, the threshold for 
depolarization is lowered and spontaneous discharges known as ectopic discharges can occur in 
abnormal locations. Consequently, the response of nociceptors to thermal and mechanical stimuli 
is increased, this phenomenon is known as peripheral sensitization.In some disease processes, 
nerve demyelination from diminished blood supply may also contribute to the production of 
ectopic discharges along the nerve fiber. 
2. Abnormal activity in axons not damaged by lesions 
Persistent neural activity and changes that occur because of nerve injury can cause chemically 
mediated electrical connections between injured nerve fibers and nearby uninjured fibers (Devor 
M et al., 2006). It is assumed that this transmission, known as ephaptic conduction (―cross 
excitation‖ or ―cross talk‖), causes nonpainful stimuli to evoke activity in these normally ―silent‖ 
nociceptors and thereby produce pain. 
3. Alterations in the expression and regulation of intracellular Ca
2+
 and modulatory 
receptors on primary afferent terminals 
Neurotransmitter release by nociceptive terminals is triggered by Ca
2+
 entry and therefore 
depends on voltage-dependent channels (Cao YQ et al., 2006). Spinal nerve ligation in rats 
induces over expression of the α2/δ Ca
2+
 channel subunit in the corresponding dorsal ganglia, 
which might lead to an enhanced neurotransmitter release (in particular glutamate) by these 
terminals thereby increasing the pain sensation as well transmission. 
4. Neuroimmune interactions resulting in enhanced and/or altered production of 
inﬂammatory signaling molecules 
 Nerve injury causes activation of peripheral immune cells. Cytokines and chemokines released 
by these immune cells, such as tumor necrosis factor-a (TNF-α), interleukins (ILs), nerve growth 
factor (NGF), and CC chemokine ligands, can cause sensitization of channels, such as TRPV1, 
and result in ﬁring of  nociceptors  at normal body temperature (Chris Pasero et al., 2004). 
5. Sensory-Sympathetic coupling and other alterations in receptor signaling 
Neuropathic pain is sometimes dependent on sympathetic nervous system activity. This is often 
referred to as ‗sympathetically maintained pain‘ (Campbel et al., 2006). It has recently been 
demonstrated that an abnormal contact develops between the sympathetic nervous system and 
the sensory nervous system following peripheral nerve injury, which may underlie the enhanced 
sensitivity to catecholamines which in turn leads to neuropathic pain (Dworkin R. H et al., 
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2002). The basic observation must be that activity in the sympathetic nervous system initiates 
abnormal impulse in sensory neurons that leads to pain perception. Several sites of coupling 
between sensory and sympathetic nervous systems have been proposed and tested in animal 
models. The following have received experimental support:- 
 Direct chemical coupling within peripheral effector sites between the noradrenergic and sensory 
neuron terminals. 
 Ephaptic nerve coupling: Observed between sensory fibres in a damaged nerve but not between 
sympathetic and sensory fibres. 
  Indirect coupling via peripheral sensitizing mechanisms involving the release of inflammatory 
mediators from sympathetic terminals and the sensitization of primary sensory neuron axons. 
 Direct coupling between the sympathetic nervous system and the sensory nervous system in the 
dorsal root ganglion. 
1.3.2. CENTRAL MECHANISMS 
1. Spinal cord—anatomical re-organization 
Spinal cord reorganization occurs in response to peripheral nerve injury. Consequence of this 
rearrangement is that second-order neurons within the spinal cord, that normally receive 
predominantly high-threshold sensory input, begin to receive inputs from low-threshold 
mechanoreceptors (Ducreux D et al., 2006). This misinterpretation of information within the 
spinal cord may result in low-threshold sensory information being interpreted as nociceptive and 
causes an allodynia condition (Cameron AA et al.,1997). 
2. Spinalcord –hyperexcitability 
Due to peripheral injury, hyperexcitability of central nociceptor neurons (central sensitization) 
occurs in the spinal cord   and causes the release of   tachykinins (neuropeptides substance P and 
neurokinin) and neurotransmitters [glutamate, calcitonin gene-related peptide, and γ-
aminobutyric acid (GABA)]. Prolonged release and binding of these substances to neural 
receptors activate the N-methyl-D-aspartate (NMDA) receptor, which causes an increase in 
intracellular calcium levels (Attal N et al., 2000). The increase in calcium levels occur through 
N-type calcium channels. These changes lead to a series of biochemical reactions in dorsal horn 
neurons. The threshold for activation is lowered, the response to stimuli is increased (in both 
magnitude and duration), and the size of the receptive field is enlarged (a greater area on the 
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neuron surface is available to receive stimuli). Collectively, these changes results in an increased 
excitability and sensitivity of spinal cord neurons to pain. 
3. Central dis-inhibition 
Central dis-inhibition occurs when control mechanisms along inhibitory (modulatory) pathways 
are lost or suppressed. This, in turn, causes abnormal excitability of central neurons thereby 
increasing the pain sensitization (Bridges D et al., 2001). 
 
Neuropathic pain is very challenging to manage because of the heterogeneity of its etiologies, 
symptoms and underlying mechanisms (Beniczky et al., 2005).Commonly used pharmacological 
treatments include antidepressants (tricyclic antidepressants [TCAs]), (selective serotonin 
reuptake inhibitors [SSRIs]), antiepileptic (anticonvulsant) drugs, topical treatments and opioid 
analgesics. Tricyclic antidepressants like (amitriptyline, clomipramine, desipramine) inhibit the 
re-uptake of biogenic amines and are also strong sodium-channel modulators (Beydounand 
Backonja, 2003; Sanchez and Hyttel, 1999). Thus TCAs may act both by enhancing dorsal horn 
inhibition and by diminishing peripheral sensitization. The serotonin noradrenaline reuptake 
inhibitors (SNRIs) such as duloxetine and venlafaxine enhance endogenous inhibitory 
mechanism thereby decreasing the pain sensitization. Anti- epileptics such as gabapentinoids, 
gabapentin and pregabalin bind to presynaptic voltage-gated calcium channels in the dorsal horn, 
reducing the release of excitatory neurotransmitters such as glutamate and substance P (Taylor 
CP, 2004).Topical lidocaine reduces pain by blocking the sodium channels at the 
periphery.Opioids like Oxycodone, Morphine sulphate act through the descending inhibitory 
pathways modulating nociceptive impulses in the dorsal horn. Tramadol is a centrally-acting 
analgesic, which has both direct opioid action and indirect monoaminergic action (S. Beniczky et 
al., 2005; Moulin D et al., 2014). 
 
Animal models are important for understanding the mechanism of neuropathic pain and 
development of effective therapy for its optimal management. Neuropathic pain models are 
developed for manifestation of clinical pain conditions. Animal models have been used widely in 
pain research as these models are capable to serve as substitute assay that can dependably 
evaluate the potency and efficacy of the pharmacological intervention (Nischaltyagi et al., 2014). 
Different types of animal models for neuropathic pain  includes peripheral nerve injury,spinal 
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cord injury induced peripheral and central pain, chemotherapeutic drugs induced pain model, 
cancer and HIV-induced pain model, post-herpetic neuralgia (PHN), diabetes and chronic 
ethanol-induced pain model, trigeminal neuralgia and orofacial pain model have been developed 
(Jaggi et al .,2009) 
Central Pain Model 
The commonly used models for central pain include spinal cord compression. Nocifensive signs 
crushing of spinal cord with forceps or aneurysm, photochemically induced injury, excitatory 
neurotoxin methods, and spinal hemi-section are generally employed (Claire E et al., 2009). 
Peripheral nerve injury models 
Numerous pain models have been developed that employ injury to a peripheral nerve for instance 
sciatic nerve which produces short-term or everlasting behavioral hypersensitivity and animal 
becomes susceptible to various behavioral tests such as tactile allodynia or thermal hyperalgesia 
(Zimmermann M et al., 2001).It includes Chronic constriction injury model (CCI or Bennett 
model), Partial sciatic nerve ligation model (PSNL or Seltzer model), L5/L6 spinal nerve ligation 
model (SNL), Sciatic cryoneurolysis model (SCN), L5 spinal nerve ligation (Bennett GJ et 
al.,1988). 
Neuropathic pain due to medical conditions 
In human beings certain ailments such as diabetes, post herpeticneuralgia and cancer are 
responsible for causing neuropathic affliction.  
 
Chemotherapy-induced peripheral neuropathy (CIPN) is defined as toxic neuropathy that results 
from the direct injury of the peripheral nervous system by chemotherapeutic agents such as 
taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, antiangiogenic or 
immunomodulatory agents. It is a frequent, dose-dependent complication of anticancer drugs.   
CIPN is considered to be one of the most common non-hematological adverse effects of a 
number of effective chemotherapeutic agents (Park SB et al., 2013). CIPN can usually affect the 
dorsal root ganglia (DRG) of the primary sensory neurons, but other sites, i.e., the nerve 
terminals (distal terminations of the branches of an axon), may also be involved.  CIPN is 
characterized by paresthesia, dysesthesia and often pain, primarily in the hands and feet (Mols F 
et al., 2014). Patients most often report sensory symptoms of numbness and tingling, followed by 
symptoms described as burning, shooting, throbbing and stabbing. All of these symptoms are 
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also associated with diminished ability to detect touch and pinprick sensations as well as 
sensorimotor impairment (M. Ewertz et al.,2015). 
 
1.4.PATHOPHYSIOLOGY 
Although the mechanism of development of neuropathic pain due to chemotherapeutic drugs is 
unknown, various hypotheses have been suggested. They are as follows: 
a) Mitochondrial dysfunction  
Abnormal mitochondrial structure and function are considered as a possible etiology of CIPN. 
Most chemotherapeutic agents cause damage to neuronal and non-neuronal mitochondria, 
leading to increased production of ROS and thus causes increased oxidative stress. The 
pathological increase in ROS production in turn can cause damage to intracellular biomolecules 
such as enzymes, proteins and lipid molecules, which in turn leads to demyelination and 
disruption of the cytoskeleton of peripheral nerves as well as sensitization of signal transduction 
processes (Carozzi et al., 2015). Furthermore, ROS can cause the activation of apoptotic 
pathways and increase production of pro-inﬂammatory mediators. These processes can cause 
further damage to mitochondria, amplifying the production of ROS and pathological processes of 
oxidative stress. 
b) Pain mediators 
After anticancer drug treatment changes in many pain mediators like cytokines, growth factors, 
ion channels etc. in the peripheral nerve, dorsal root ganglion, and spinal cord                           
have been postulated. Mitogen-activated protein kinases and extracellular signal-related kinases 
may play important roles in CIPN; activation of these kinases is involved in chemotherapy 
induced apoptosis (Lobert et al., 1996). In CIPN animal model it was found that there was an 
increase in the TNF-α level, IL-1, and IL-6 in the sciatic nerve and spinal cord. Fos expression 
was activated significantly in the superficial, intermediate, and deep layers of the spinal cord in a 
CIPN animal model 
c) Abnormal spontaneous discharge in A and C fibers 
Peripheral and central sensitization may be involved in the development of CIPN.  Abnormal 
spontaneous activity in Aβ, Aδ, and C fibers has been observed in vincristine, paclitaxel, 
oxaliplatin, and bortezomib induced peripheral neuropathy (Park, 2014). Moreover, C-fiber 
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nociceptors showed significant hyper responsiveness to supra-threshold tactile and thermal 
stimuli in a CIPN animal model. 
d) Others   
Peripheral neuropathy induced by paclitaxel, oxaliplatin, and vincristine  induced                                        
is caused by decreased numbers of intra-epidermal sensory fibers and increased numbers of 
epidermal Langerhans cells and resembles a traumatic-nerve-injury-induced neuropathic pain 
model (CCI, sciatic nerve transection) (Jessica et al., 2015). The CNS has also been shown to be 
involved in CIPN both directly and indirectly. 
 
 
Fig: 3. Pathophysiology of chemotherapy induced neuropathic pain 
Vincristine, also known as leurocristine is one of the most common chemotherapeutic agent used 
to treat several types of malignanacies such as leukaemia, lymphomas and sarcomas (Balaji et 
al., 2015).These agents exert their anti-tumor efﬁcacy by inhibiting mitosis through binding to 
tubulin in mitotically active cells, disrupting microtubule formation in the mitotic spindle. Thus, 
clinical application of these agents is often associated with dose-dependent painful neuropathy 
owing to damages to the peripheral axons (Emiliano S. Higuera et al., 2004). 
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Vincristine belongs to the family of vinca alkaloids that can be obtained from the Madagascar 
periwinkle Catharanthus roseus. Vincristine is created through the semi-synthesis coupling of 
indole alkaloids vindoline and catharanthine in the vinca plant. It can also be synthesized through 
a stereocontrolled total synthesis technique which retains the correct stereochemistry at C18 and 
C2. The absolute stereochemistry at these carbons is responsible for vincristine‘s anticancer 
activity. 
 
Vincristine treatment is limited by a progressive sensorimotor peripheral neuropathy (Smith et 
al.,2016). This occurs in two major stages. In the early stage, the peripheral axons are damaged 
by vincristine and the principal symptoms are paresthesias and dyesthesias. In the later 
stage,which occurs more frequent at higher doses, axons are lost and the principal finding is loss 
of motor function. Vincristine affects the structure and function of peripheral nerve fibres.It has a 
great binding affinity to protein subunits of microtubules, tubulin, dissolution of axonal 
microtubules and causes the proliferation of neurofilaments. 
Symptoms of neuropathy can be present soon after initiation of vincristine therapy but usually 
develops within several weeks and generally worsen with increasing cumulative doses of the 
drug.VIPN can be divided into sensory, motoric and autonomic components, with tendon 
reﬂexes, vibration sensitivity and strength mostly affected in the ﬁrst year of treatment. Sensory 
neuropathy is characterized by numbness, tingling and neuropathic pain in the upper and lower 
extremities (Grisold W et al., 2012).Vincristine-induced motor neuropathy is characterized by 
weakness in the upper and lower extremities and the development of wrist- or foot-drop due to 
impaired dorsiﬂexion that arises from damage to peripheral nerves. This is accompanied by gait 
abnormalities, cramps, and loss of or reduction in deep tendon reﬂexes which can be severe. 
Typical symptoms of autonomic neuropathy are constipation, urinary retention, and orthostatic 
hypotension.  
1.5. PATHOLOGICAL MECHANISMS CONTRIBUTING TO VIPN 
1.Oxidative stress and apoptotic pathways  
Vincristine causes dysregulation and structural modiﬁcation of neuronal mitochondria, leading to 
activation of apoptotic pathways, alteration in neuronal excitability and dysfunction of glial cells 
(Higuera E. S et al., 2004). The effect of vincristine on mitochondria involves altered 
mitochondrial Ca
2+
 signaling. 
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2. Calcium homeostasis 
Changes in the intracellular Ca
2+
 concentration inﬂuence membrane excitability, 
neurotransmitter release and gene expression of neuronal and glial cells 
3. Axon degeneration 
 Long-term administration of chemotherapeutic agents results in axonal degeneration.There will 
be loss of large myelinated, small unmyelinated (more rarely), and intra-epidermal nerve ﬁbers 
(IENF) which may be connected to the development of sensory-motoric peripheral neuropathy. 
Intraepidermal nerve ﬁbers are unmyelinated or thinly myelinated nociceptors located in the 
dermis and are necessary for the sensation of pain arising from the periphery (Legha S.S et al., 
1986). Additionally, loss of myelin and changes to the axonal cytoskeleton may alter the 
structure and function of peripheral nerves, which in turn may contribute to the development of 
altered pain perception.  Vincristine causes the impairment of β-tubulin assembly and leads to 
severe alterations in axonal microtubules, axonal swelling and myelinated and unmyelinated 
fiber damage. 
4. Changes in neuronal excitability 
Chemotherapeutic agents cause changes to peripheral nerve excitability that contribute to the 
development of sensory peripheral neuropathy. These are likely caused by altered expression and 
function of a range of ion channels—including voltage-gated sodium (NaV), voltage-gated 
potassium (KV) and transient receptor potential (TRP) channels (Johnson I. S et al., 1963). 
Vincristine-induced neuropathy has also been attributed to activation of TRPA1 and TRPV4 via 
the generation of reactive oxygen species and also may be due to the disruption of TRP channel 
function due to altered association with microtubules. 
5. Activation of the immune system and inﬂammation 
Vincristine induces the expression of integrins (immune markers) on the surface of endothelial 
cells which allows macrophages expressing the CX3CR receptor to adhere to the endothelium 
and to migrate into nervous tissue. Activation of monocyte-macrophages by the chemokine 
CX3CL1 also lead to production of ROS and subsequent activation of TRPA1 (Hana Starobova 
and Irina Vetter 2017). Vincristine   enhances the binding of the STAT3 (Signal Transducer and 
Activator of Transcription 3) to the CXCL12 gene promotor (Xu et al., 2017), causing up-
regulation of C-X-C Motif Chemokine Ligand 12 in dorsal horn ganglia. The activation of 
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CXCR4 receptors in   turn leads to an increase in intracellular Ca
2+
 and chemotaxis of immune 
cells to the site of inﬂammation.  
Pterocarpus marsupium Roxb. (Leguminosae), (PM) Malabar kino, Indian kinotree or vijayasar 
is a plant drug belonging to the group called rasayana in ayurvedic system of medicine .These 
rasayana drugs are immunomodulators and relieve stress in the body. It is widely distributed in 
central, western and southern regions of India. Parts of the Indian kino have long been believed 
to have many medicinal properties. Heartwood juice of this plant is known to contain 
polyphenolic compounds (like flavonoids, diphenylpropane derivatives, and sesquiterpenes), 
which show strong antioxidant, anti-inflammatory, antidiabetic, antimicrobial, and anticancer 
activities and is used for the treatment of diabetes, jaundice, ulcer, gastritis, etc.  In the ayurvedic 
Pharmacopoeia of India, it has been described to be used in the treatment of krmiroga (worm 
infection), kustha (leprosy), prameha (diabetes), pandu (anemia), and medodosa (obesity). 
 
Fig: 4. Pterocarpus marsupium plant 
Previous studies have showed the antioxidant (Gupta P et al.,2016) (Chakraborty A et al.,2010), 
antimicrobial(Gayathri M et al.,2009), antidiabetic, anti-inflammatory, and analgesic activities of 
different extracts of P. marsupium (Dipak Raj Pant et al., 2017). Its main chemical constituent is 
a glucosidal tannin namely kinotannic acid. Several other chemical constituents like 
pterostilbene, (-)-epicatechin, pterosupin, marsupsin, etc. have been identified and isolated. 
 
Neuropathic pain is widely recognized as one of the most difficult pain syndromes to manage, 
and outcomes often are unsatisfactory. Epidemiological research in this area can be problematic 
and the reasons for this are multifactorial. Patients experiencing pain may try numerous 
therapies, including traditional medicinal approaches for relief. Pain relief is the most frequently 
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cited reason that people seek complementary and alternative medicine. Since Pterocarpus 
marsupium capsules has shown its activity in diabetic neuropathy as well as analgesic activity in 
the previous studies the present study was designed to evaluate its protective effect in vincristine 
induced peripheral neuropathy. 
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2.  LITERATURE REVIEW 
Ahmet Hoke, 2012 discussed about the animal models which were used to induce peripheral 
neuropathies such as diabetic peripheral neuropathy, chemotherapy-induced peripheral 
neuropathy and HIV-associated sensory neuropathy. It was found that the similarity between 
these models is the comprehensive use of pathological, electrophysiological, and behavioral 
outcome measures (evaluation of distal sensory axons in the skin using a simple 
immunohistochemical stain) that mimic the human disease.  
Xia Zhang et al., 2017 suggested that peripheral neuropathy is one of the major side effects 
associated with chemotherapeutic agents. This study mainly focused on the various mechanisms 
of neuropathic pain such as peripheral, central, inflammatory as well as chemotherapy induced 
neuropathic pain. 
Park, 2014 examined that anti- cancer chemotherapeutics can cause painful peripheral 
neuropathy. It affects the sensory, motor and autonomic functions.   Symptoms may occur at any 
time during the course of chemotherapy or even after discontinuation of treatment. In this study 
possible mechanism of neuropathy such as mitochondrial dysfunction, various pain mediators, 
abnormal spontaneous discharge in A and C fibers were discussed. 
Ahmet Hoke et al., 2014 evaluated CIPN in rodents by behavioral, electro-physiologic and 
pathologic parameters. Behavioral testing was assessed by various methods such as mechanical 
allodynia, mechanical hyperalgesia,thermal hypo- or hyperalgesia,sensory–motor coordination. 
They are used to evaluate evoked sensory responses. Electrophysiological testing was assessed 
by motor nerve conduction studies and sensory nerve conduction studies. It evaluates the 
integrity of large myelinated axons.  Histologic analyses were done by evaluating theneuronal 
morphology and numbers, nerve morphometry and by intraepidermal nerve fiber density. It 
evaluates the degree of axonal degeneration or changes in neuronal cell body. 
Yaqin Han et al., 2013 evaluated the structural changes in peripheral nerves such as 
neuronopathy, axonopathy and/or myelinopathy, especially intra-epidermal nerve fiber (IENF) 
degeneration which are mainly caused by mitochondrial dysfunction and oxidative stress caused 
by the cancer chemotherapeutic agents. .  It was found that CIPN was characterized by multiple 
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sensory changes including the development of (i) mechanical allodynia, in which light pressure 
or touch that would normally be perceived as innocuous, evokes pain (ii) cold allodynia whereby 
cold temperature evokes a painful sensation (iii) slowing of SNCV and (iv)loss of heat 
sensitivity. 
Jessica A Boyette-Davis et al., 2015 provided information regarding the mechanism of 
chemotherapy induced neuropathic pain which include both cellular and molecular mechanisms.  
It has been found that processes found to be influenced during CIPN include an increased 
expression of inflammatory mediators, primarily cytokines, which can create cascading effects in 
neurons and glia. It was noted that in CIPN there was a change in ion channels, 
neurotransmission,intracellular signaling and structures. 
Preet G. S. Makker et al ., 2017evaluated the distinct pathological changes caused by Paclitaxel 
(PTX) and Oxaliplatin (OXA) in the peripheral immunity and neuroinflammation, It was found 
that PTX and OXA were associated with an increase in CD4+ and CD8+ T-cells in the blood.  
OXA caused a significant reduction in immunosuppressive cells PTX selectively caused marked 
phenotypic changes in both the peripheral and central nervous systems. 
Chuanyin Hu et al., 2016 evaluated the efficacy of Fucoidan on vincristine-induced neuropathic 
pain.  It was observed that only with repeated Fucoidan (50, 100 or 200 mg/kg) administration 
there was attenuation in vincristine-induced mechanical and cold allodynia in a dose-dependent 
manner. The analgesic effects of Fucoidan contributed to an upregulation in the expression of 
GABA-B receptor in the spinal cord. 
Gong SS et al., 2016 designed a study to investigate the effect of Matrine (MT) on VCR-induced 
neuropathic pain. MT ameliorated the nociceptive pain sensation (mechanical and cold allodynia, 
thermal and mechanical hyperalgesia), and alleviated electrophysiological and histopathological 
injury. It was found that Matrine caused a suppression of inflammatory response through 
regulating the expression of MPO, TNF-α, IL-6 and IL-10, as well as inhibiting oxidative stress 
and also decreased the calcium accumulation. 
Jing Xu, et al., 2016 demonstrated the effect of Methyl-cobalamin on vincristine induced 
neuropathy.  In this study it was found that MeCbl inhibited the loss of IENF and decreased 
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atypical mitochondrial prevalence. Moreover MeCbl not only inhibited the overproduction of 
TNF-α but also increased the expression of IL-10 in the spinal dorsal horn. It also inhibited the 
activation of NADPH oxidase and the downstream NF-κB pathway which resulted in the 
rebalancing of pro-inflammatory and anti-inflammatory cytokines in the spinal dorsal horn. 
Soh Katsuyama et al., 2014 investigated the attenuation of vincristine-induced mechanical 
allodynia in mice by Milnacipran and Duloxetine. It was observed that SNRIs such as 
Milnacipran and Duloxetine were used for the treatment of acute, persistent, neuropathic pain as 
supplementary analgesics and also they showed significant antinociceptive effects against 
nociceptive and inflammatory pain. 5-HT and NA are implicated in modulating descending 
inhibitory pain pathways. The antiallodynic effects of SNRI in neuropathic pain models were 
predominantly attenuated by the noradrenergic system rather than by the serotonergic system at 
the spinal level. It has been reported that activation of the descending noradrenergic system and a 
subsequent increase of NA in the spinal dorsal horn in a rat neuropathic pain model contributed 
to the antihyperalgesic effects of antidepressants such as TCAs and SNRIs. The neuronal NA 
transporter is functionally expressed in cultured rat astrocytes and SNRI potently inhibits NA 
uptake in these cells. 
Byoung Yoon Park et al., 2010 examined the antinociceptive effect of Memantine (N-methyl-D-
aspartate receptors antagonist) and Morphine (opioid agonist) on vincristine-induced peripheral 
neuropathy.In this study it was examined that Memantine produced anti nociceptive effect due to 
its antagonistic activity on NMDA receptor. Memantine has been used to treat Parkinson's 
disease, spasticity, convulsions, vascular dementia, Alzheimer's disease, complex regional pain 
syndrome and phantom limb pain. Morphine exhibited its analgesic activity by acting through µ-
opioid receptors. 
Bilin Nie et al., 2017 demonstrated that intrathecal injection of Dexmedetomidine (DEX) or 
intraperitoneally administered Ulinastatin (UTI) significantly reduces mechanical allodynia 
induced by vincristine. It was observed that the antinociceptive effect was due to the 
upregulation of IL-10 expression and activation of α2-adrenergic receptor in dorsal root ganglion.  
It was also noted that when DEX and UTI were given in combination there was a synergistic 
interaction. It was demonstrated that inflammation was closely related to neuropathic pain 
induced by chemotherapeutic drugs. IL-10 may be a powerful anti-inflammatory factor that can 
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suppress pro-inflammatory cytokines such as TNFα, IL-1, IL-6 and IFNγ implicated in 
neuropathic pain. IL-10 was able to reduce nociceptor sensitization and produce analgesia. 
Intrathecal IL-10 also suppresses CSF levels of at least IL-1and IL-1-mediated pain induced by 
intrathecal dynorphin. 
Terumasa Chiba et al., 2017 investigated that there was an up-regulation of transient receptor 
potential vanilloid 1 (TRPV1) in peripheral neuropathy caused by anti-cancer drug treatment. In 
this study it was found that vincristine-treated rats developed mechanical allodynia/hyperalgesia 
and there was an increased level of TRPV1 protein expression in the small diameter DRG 
neurons.  It was noted that C-fiber neurons began to express TRPV1 after vincristine treatment. 
In contrast, TRPV2 protein expression did not change in DRGs after treatment with vincristine. 
Ting Xu et al., 2017 demonstrated that oral application of Magnesium-L-Threonate attenuated 
vincristine-induced allodynia and hyperalgesia. From this study it was evident that vincristine 
treatment activated TNF-α/NF-κB signaling by reduction of intracellular free Mg2+ of DRG 
neurons.  It was found that oral application of L-TAMS completely blocked up-regulation of 
TNF-α but partially blocked activation of NF-κB induced by vincristine. Thus it clearly 
demonstrated that L-TAMS could not completely prevent the vincristine-induced allodynia and 
hyperalgesia, as activation of NF-κB also leads to transcription of many other pro-inflammatory 
genes, such as interleukin-1β, which are considered to be important for nociceptive sensitization. 
Kiguchi N et al., 2009 examined the involvement of inflammatory mediators in 
neuropathic pain caused by vincristine. It was observed that systemic treatment with vincristine 
damages Schwann cells and DRG neurons.  It was observed that the inflammatory mediators 
released by these cells may recruit macrophages in the PNS. Macrophages released the 
inflammatory cytokine IL-6, which elicited neuro-inflammation and led to the development of 
neuropathic pain. Secondary signal transduction of pain to the CNS activated microglia and 
astrocytes, and these activated glial cells contributed to the development and maintenance of 
neuropathic pain in the CNS through production of inflammatory cytokines (e.g., TNF- α). 
Elizabeth K. Joseph et al., 2006 demonstrated that mitochondrial electron transport chain and       
ATP play an important role in peripheral pain mechanisms. It was found that inhibitors of 
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mitochondrial electron transport chain complexes I, II, III, IV, V exhibited antinociceptive effect 
in models of toxic and metabolic painful peripheral neuropathy and also for the mechanical 
hyperalgesia induced by TNF α. Since the mitochondrion is the major source of cellular ATP, 
this study provided further support for the role of mETC in peripheral pain mechanisms 
including a role of its end product, ATP. From the study it can be concluded that mETC and its 
end product, ATP, play an important role in peripheral pain mechanisms.  mETC chain was 
important in inflammatory as well as neuropathic pain models whereas ATP contributed  only to 
peripheral neuropathy.  
Anita Barzegar-Fallah et al., 2014 designed a study to investigate the suppressive effect of 
Tropisetron (5-HT3 receptor antagonist) against VCR induced neuropathy and also to ensure 
whether this effect was exerted through the 5-HT3 receptor. Tropisetron is used as an antiemetic 
or in chemotherapy-induced emesis. In -vitro and in vivo studies have shown that tropisetron 
exerts immune modulatory and anti-inflammatory properties. It also inhibited IL-2 gene 
transcription and proliferation in antigen-stimulated human T cells via blockade of 
calcineurin/NFAT-dependent signaling pathway. It was found that due to nerve injury there was 
an increase in the intracellular calcium level which led to calcineurin activation and 
dephosphorylation of NFAT and its translocation to the nucleus. Finally these events resulted in 
the release of several cytokines, including IL-2, IL-4 and TNF and neuronal cell apoptosis. 
Tropisetron act as a neuroprotective agent for prevention of VCR-induced neuropathy via a 
receptor-independent pathway. 
Stefanie Geisler et al., 2016 designed a study to evaluate whether genetic deletion of SARM-1 
decreases axonal degeneration in a mouse model of neuropathy induced by VCR. It was 
observed that SARM-1 is necessary for the development of VIPN. Activation of the SARM-1 
pathway rapidly depleted NAD
+
 followed by loss of ATP which resulted in morphological 
degeneration of the axon. To block SARM-1-induced axonal degeneration in –vitro, NAD+ has 
to be maintained. 
Seunguk bang et al., 2016 demonstrated the anti-allodynic (mechanical and cold allodynia) 
effect of TheoesberivenF (Melilotus extract and proxyphylline) in VCR induced neuropathy. It 
was reported that ethyl acetate fraction of Melilotussuaveolens reduced the production of pro-
inflammatory cytokines, including IL-6 and TNF-α via the suppression of nuclear factor-
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κBactivation. Coumaric acid, a component of Melilotus extract, has been reported to exert an 
anti-inflammatory effect by reducing the expression of TNF-α. A coumarin derivative has 
showed its activity against neurotoxicity by improving the mitochondrial function. 
Melilotus extract exhibited its antioxidant effect by inhibiting the formation of TBARS, pro-
oxidant H2O2 and superoxide anion.  
Dipak Raj Pant et al., 2017 designed a study to evaluatethe phytochemical constituents and to 
study the antioxidant, antimicrobial, anti-diabetic, anti-inflammatory and analgesic activities of 
extracts from stem wood of PM. The study revealed that PM is a source of various 
phytoconstituents such as alkaloids, glycosides, saponins, tannins, proteins, carbohydrates, 
cardiac glycosides, flavonoids, and terpenoids. The acetone and IPA extract and ethanol 
extract showed antioxidant activity and this may be due to the presence of phenolic 
compounds.Acetone and IPA extract showed antibacterial activity only against Gram-positive 
bacteria and ethanol extract was inactive against all the bacteria.  The acetone and IPA extract 
also showed potential anti-inflammatory activity. Ethanol extract exhibited anti -diabetic and 
analgesic activities.  
Pankaj Gupta et al., 2016 evaluated the effect of alcoholic extract of heartwood of PM on in- 
vitro antioxidant, anti-glycation, sorbitol accumulation and inhibition of aldose reductase activity 
(ALA). It was found that the alcoholic extract exhibited antioxidant activity due to the presence 
of phenolic compounds. Due to the presence of high phenolic compounds and flavonoid contents 
in the alcoholic extract it inhibited the AGEs formation (antiglycation) either by decreasing the 
ROS formation or by scavenging .The alcoholic extract inhibited the ALR and prevented the 
accumulation of intracellular sorbitol. 
Prarthana Chakraborty et al ., 2014 demonstrated that  α-Dihydroxychalcone-glycoside (α-
DHC) isolated from the heartwood of Pterocarpus marsupium inhibited LPS induced MAPK 
activation and up regulated HO-1 expression in murine RAW 264.7 
macrophage.Theantiinflammatory activity of α-DHC was exerted by  down-regulating MAPKs 
and restricting nuclear stabilization of NF-κB that inhibited  the over expression of pro-
inflammatory cytokines as well as inflammation mediating enzymes. It disrupted the Nrf-2–
Keap-1 complex leading to induction of cytoprotective enzymes that indirectly repress the 
expression of inflammatory mediators. It has been observed that α-DHC reduces production of 
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NO as well as release of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and also suppressed 
COX-2 and iNOS expression at both protein and mRNA levels.   
Ajanta Chakraborty et al., 2010 evaluated the cytotoxic, anti-proliferative and anti-oxidant 
properties of pterostilbene isolated from PM. The study demonstrated that pterostilbene plays an 
important role in the apoptosis of two different types of cancer cell lines MCF-7 and PC3.It 
inhibited cellular proliferation and induces apoptosis by the production of nitric oxide  
Mohammadi M et al ., 2009 designed a study to evaluate the antioxidant properties of extract of 
stem bark extract of PM .The results demonstrated  that during  acute exposure to alcohol, PM 
extract helps to maintain cholesterol as well as triglyceride levels. PM extracts reduced the free 
radical generation and this was due to the presence of flavonoids. PM extract showed strong 
antioxidant activity in all in vitro assays and protects liver cells from ethanol induced oxidative 
stress 
Maruthupandian A et al., 2011 investigated the antidiabetic, antihyperlipidaemic and 
antioxidant activity of PM in alloxan induced diabetic rats. The ethanolic extract of PM showed 
hypoglycemic effect by the induction of insulin release from pancreatic cells of diabetic rats .The 
hypolipidemic effect was due to the inhibition of fatty acid synthesis. It was also observed that 
there was a reduction in the activity of SOD, CAT, GPx, GSH and GR in alloxan induced rats 
and this was due to the decrease lipid peroxidation and by normalizing the antioxidant system. 
Kirana Halagappa et al., 2010 designed a study to investigate the effect of aqueous extract of 
PMon elevated inflammatory cytokine, tumor necrosis factor (TNF)-α in Type II diabetic rats.  It 
was observed that there was a reduction in blood glucose level which was due to the enhanced 
insulin secretion by regeneration of β-cells.Decrease in elevated TNF-α by the aqueous extract 
of PM along with its blood glucose lowering effect suggested that the immunomodulatory 
property of the drug could be related with its potential anti-diabetic activity. It was noted that 
modulation of cytokine TNF-α by the aqueous extract of PM had indirect effect on PPAR-γ 
expression.  
Dhanabal SP et al., 2006 evaluated the antidiabetic activity of various subfractions of the 
alcohol extract of the bark of PM in alloxan-induced diabetic rats.  From the results it can be 
concluded that the PM decreased the glucose level (antihyperglycaemic) by increasing the 
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insulin secretion from the remnant or regenerated beta cells. It also resulted inhyperlipidaemic 
conditions. 
Suresh K et al., 2012 investigated the insulinotrophic and insulin-like effects of a high molecular 
weight aqueous extract of PM (10KR). It was observed that the aqueous extract of PM (PME) 
stimulated the insulin secretion in response to hyperglycaemic culture conditions .The results 
demonstrated that both PME and 10KR had beneficial effects on lowering blood glucose and 
sensitizing the insulin responsiveness after a glucose challenge. It was noted that 10KR had 
potent antidiabetic properties both in -vitro and in- vivo 
M. Gayathri et al., 2009 examined the antimicrobial activity of Hemidesmus indicus, Ficus 
bengalensis and Pterocarpus marsupium. The aqueous extracts of the roots of H. indicus and the 
bark F. bengalensis and P. marsupium Roxb exhibited significant antibacterial activity against 
tested bacterial strains. Presence of tannins and saponins in higher concentration than the other 
phytochemicals suggested that these phytochemicals are responsible for the antibacterial activity. 
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3. AIM AND OBJECTIVE 
AIM 
 To evaluate the neuroprotective effect of Pterocarpus marsupium marketed capsules 
against vincristine induced neuropathy in rat model. 
 OBJECTIVE 
 To study the effect of P.marsupium on behavioural models for neuropathic pain. 
 To study the effect of P.marsupium on excitatory neurotransmitters (glutamate and 
aspartate) in vincristine induced rats. 
 To study the effect of P.marsupium on histopathology of sciatic nerve. 
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4. PLAN OF STUDY 
Phase I:  
Optimization of vincristine and induction of neuropathic pain in  Female Sprague Dawley rats 
Phase II: 
BEHAVIOURAL TESTS  
 Hot plate test 
 Randall-Sellito test 
  Electronic Von Frey  test 
 Formalin test 
 Sciatic functional index 
 
Phase III: 
NEUROCHEMICAL ESTIMATION  
 Glutamate 
 Aspartate 
Phase IV: 
HISTOPATHOLOGICAL EVALUATION 
 Histopathology of sciatic nerve  
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Methodology -I 
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Day 0 Day 12 Day 21 
Vincristine 75µg/kg, i.p PM 100&200 mg/kg, p.o 
Behavioral screening 
*Hot plate test 
*Randall sellitto test 
*Electronic Vonfrey  test 
Formalin test 
Sciatic Functional Index 
Sciatic nerve & Brain isolation 
Histopathology Neurochemical 
Estimation 
(Aspartate & Glutamate) 
Vincristine 75µg/kg i.p and PM 100&200 mg/kg p.o 
Co-administration 
Day 0 
 
Day 12 
 
Day 21 
 
Behavioral screening 
Formalin test 
Sciatic Functional Index 
 
*Hot plate test  
*Randall sellitto test 
*Electronic Vonfrey test 
Sciatic nerve & Brain isolation 
Histopathology Neurochemical Estimation 
(Aspartate & Glutamate) 
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5. MATERIALS AND METHODS 
 
5.1. Chemicals and instruments used: 
The chemicals used for the present study were tabulated in table 1. 
Table 1:List of chemicals used 
Chemicals Manufacturer 
Vincristine  Cipla, India. 
Pterocarpus marsupium VasuPharma, India. 
Pregabalin Sun pharma, India. 
Chloroform  Reachem, India. 
Sodium citrate  HI-MEDIA, India. 
Formaldehyde Reachem, India. 
Carboxy Methyl Cellulose   OTTO, India. 
Millipore water Direct-Q, India. 
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The instruments used for the present study were tabulated in table 2. 
Table 2:List of instruments used 
Instrument Manufacturer 
Hot plate Analgesiometer Dolphin 
Vonfrey Filament BIOSEB 
Randall- Sellitto Harvard 
Refrigerated centrifuge Eppendrof 
Deep freezer Cryo scientific systems 
Vortex TARSONS 
HPTLC CAMAG 
 
5.2. Animals: 
Female wistar rats of average weight (150-250g) were used for this study.The animals used for 
this study were obtained from PSG IMS&R (PSG Institute of Medical Science and Research) 
animal house and all the experimental protocol was approved by the institutional animal ethics 
committee(IAEC) proposal number 357/2017/IAEC. The rats were grouped and housed 
(6animals/cage) with husk as a bedding material in a room with controlled temperature of 
25±1°C and a reversed light –dark cycle (12h\12h). Normal feed pellets and pure water ad 
libitum were provided for the animals throughout the experiment. Animals were acclimatized to 
laboratory condition for 1 week prior to experiments. The experiments were performed 
according to the guidelines of the committee for the purpose of supervision and control of 
experiment on animals (CPCSEA), Government of India 
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5.3. Pterocarpus marsupium capsules: 
Pterocarpus marsupium capsules were obtained from VASU Healthcare Pvt. Ltd,Gujarat. It is a 
safe and effective herbal preparation that has been found to reduce glucose absorption from the 
gastrointestinal tract and improves insulin and pro-insulin levels. Each capsule contains 300mg 
bark extract of P.marsupium. 
 
 
Fig: 5. Pterocarpus marsupium capsules 
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5.4. Methodology: 
5.4.1. Induction and assessment of peripheral neuropathy by vincristine 
Table: 3. Groupings of animals 
GROUPS TREATMENT NUMBER OF 
ANIMALS 
GROUP –I Control (CMC + Saline)* 6 
GROUP –II 
Vincristine +Saline 
(75µg/kg,i.p)* 
6 
GROUP –III 
Vincristine +Pregabalin 
(75µg/kg, i.p+10mg/kg ,p.o)* 
6 
GROUP –IV 
Vincristine+P.Marsupium 
(75µg/kg, i.p+100mg/kg ,p.o) 
6 
GROUP –V 
Vincristine+P.Marsupium 
(75µg/kg ,i.p+200mg/kg ,p.o) 
6 
GROUP –VI 
Vincristine+P.marsupium(100mg/kg) 
(co-administration) 
6 
GROUP-VII 
Vincristine+P.marsupium(200mg/kg) 
(co-administration) 
6 
* Indicates that the animals were obtained from Department Animal House. 
Vincristine sulphate injection (1mg/ml) was diluted in normal saline just before the 
administration to get a concentration of 75µg/ml.  The injection was given in a dose of 75µg/ kg 
(IP) once per day for 10 days in 5days on 2 days off and 5 days on cycle for the rats depending 
on their body weight.  Peripheral neuropathy was confirmed after 10 consecutive days of 
vincristine administration. Nociceptive thresholds in these animals were assessed by subjecting 
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them to behavioral studies such as hot plate test for thermal hyperalgesia , Randall  Sellito test 
for mechanical hyperalgesia,  electronic Von Frey test for mechanical allodynia (0
th
 day,12
th
 day, 
21
st
day), formalin test for chemical induced nociception and sciatic functional index test for 
screening the neurophysiology of the nerve (21
st
 day) (Muthuraman et al. ,2011). Neurochemical 
estimation of excitatory neurotransmitters such as glutamate and aspartate in rat brain were done. 
Histopathological study of sciatic nerve was carried out. 
5.4.2. Treatment schedule 
The animals were divided into seven groups of six animals each. The study period was for 21 
days. The first group is normal control in which the animal  receives 0.3%CMC, second group 
consists of negative control (only vincristine treated), third group consists of standard in which 
the  animal  is treated with  Pregabalin10mg/kg after the induction of neuropathic pain by 
vincristine, fourth and fifth group consists of animals treated with test drug (Pterocarpus 
marsupium 100 and 200 mg/kg  post administration) after the induction of neuropathic pain,sixth 
and seventh group consists of animals receiving vincristine as well as test drug 
Pterocarpusmarsupium 100 and 200 mg/kg(co-administration) with a time interval  of 1 hour. 
The standard (Pregabalin 10mg/kg) and the test drug (P.Marsupium 100 & 200mg/kg) dissolved 
in 0.3%w/v carboxymethylcellulose and were given orally. 
5.5. Behavioral examination : 
The animals were subjected to various behavioural studies such as hot plate, Randall-Sellito, 
Von Frey, formalin and sciatic functional index test. 
5.5.1. Hot plate test (Thermal hyperalgesia) 
The animals were individually placed on a hot plate (Eddy’s hot plate) maintained at 55±1°C 
within the restrainer. The timer was started .The  reaction time (in seconds) or  latency period or 
nociceptive threshold  was determined  as the time taken for  the  rats  to react to the thermal pain 
by  either licking their  paws or jumping . The cut off time was fixed to 10 sec in order to avoid 
damage to the paw (Sook-Ha Fan et al., 2014). 
 
Materials & methods  
 
Department of Pharmacology, PSGCOP Page 32 
5.5.2. Randall Sellito test (Mechanical hyperalgesia) 
Mechanical hyperalgesia was evaluated by the Randall Sellito test using a paw pressure 
analgesia instrument. Before the test each animal received 5mins of handling and then it was 
placed into a cloth and immobilized with the same hand used to hold the tested paw. The test 
consists of application of mechanical force in which the tip of the device was applied on to the 
dorsum of   the rat’s hindpaw. The nociceptive threshold (expressed in grams)was determined 
when the rat exhibited a flinch response and attempted to withdraw its hind paw. The cut off 
pressure of 450g was maintained to avoid damage to the paws (Muthuraman et al., 2011). 
5.5.3. Electronic Von Frey test (Mechanical allodynia) 
Mechanical allodynia was assessed by measuring the withdrawal threshold of the hind paw in 
response to a mechanical stimulus using an electronic Von Frey esthesiometer. Each animal was 
placed on a metallic grid floor in a plastic observation chamber that provided access to the 
plantar surface of the hind paw. The animals were allowed to acclimate in a quiet, subdued light 
environment to the environment for 10 min. A rigid tip attached to the meter was applied to the 
plantar surface of the hind paw from under the floor. At threshold the rats respond by flicking its 
hind paw away from the stimulus. The cut off force between 150-200grams was maintained to 
avoid damage to the paws. (Yoshihiro Takahashi et al., 2015) 
5.5.4. Formalin test (Chemical induced pain model) 
The experiment was conducted in a quiet, temperature controlled (20-30°C) room. Rats were 
acclimated to the individual observation chambers 1hr prior to the testing. 50 µL of 2.5%w/v 
solution of formalin was injected into the intraplantar surface of the rat hind paw. After injection 
the animals were placed immediately into the observation chamber. The amount of time the 
animal spent in licking and showing the elevation of the injected paw were taken as the indicator 
of pain response .The response was noted for the initial 10 mins (early phase) which starts 
immediately after  the formalin injection. This phase is probably due to the direct chemical 
stimulation of nociceptors. The response was then noted for the last 20mins (delayed phase) 
which starts approximately 15 to 20 mins following formalin injection and it probably suggests 
that peripheral and inflammatory processes are involved. Time interval between the two phases 
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was 10mins .Control and test drugs were administered 30mins prior to the formalin injection 
(Meunier et al., 1998). 
5.5.5. Determination of Sciatic functional index (SFI) (Functional loss) 
SFI has been used as one of the evaluation methods of walk track analysis.  It is used in assessing 
the nerve function and motor function. The rat hind paws were dipped in ink and they were 
allowed to walk freely and SFI was measured from the images obtained on a white paper. A 
single walk by each animal was enough to obtain adequate footprints on the white paper. The 
footprints were analysed and the following foot lengths are obtained. 
 Print length (PL):   The distance from heel to toe   
 Toe spread (TS):     The distance from the first toe to the fifth to 
  Intermediary toe spread(IT): The distance from the  second to the  fourth toe 
All these measurements were taken from the experimental (E) and normal sides (N) . 
The factors were calculated as follows: 
Print Length Factor (PLF) = (EPL-NPL)/NPL 
Toe Spread Factor (TSF) = (ETS-NTS)/NTS 
Intermediary Toe Spread Factor (ITF) =(EIT-NIT)/NIT 
Where, EPL = experimental print length 
 NPL = normal print length 
 ETS = experimental toe spread 
 NTS = normal toe spread 
 EIT = experimental intermediary toe spread 
 NIT = normal intermediary toe spread  
These factors were incorporated into the SFI formula derived by Bain et al.,1989; 
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SFI=-38.3 *PLF + 109.5 * TSF + 13.3 x*ITF - 8.8  
An SFI of 0 is normal and -100 indicates total impairment due to a complete transaction of the 
sciatic nerve. (Bain JR et al., 1989) 
5.6. Neurochemical Estimation: 
Simultaneous estimation of glutamate and aspartate in rat brain using HPTLC: 
Excitatory neurotransmitters like L-glutamic acid and L-aspartic acid were measured in rat brain 
using high performance thin layer chromatography (HPTLC) coupled with densitometer. 
Chromatographic conditions:- 
 Stationary phase: Silica gel 60 F 254 
 Mobile phase: n-butanol : glacial acetic acid : water (65:15:25v/v) 
 Chamber saturation time: 3hrs 
 Instrument : HPTLC(Camag-version1.3.4) 
 Applicator (injector): Linomat  V 
 Scanner:  Camag TLC scanner III 
 Developing  chamber: Twin trough glass chamber (20×10) 
 Developing mode: Ascending mode(multiple development) 
 Detection reagent: 0.2% ninhydrin in acetone 
 Scanning wavelength: 486nm 
 Experimental condition :  25±2°C 
 Temp/RH:  55–65% 
Preparation of Standard Solutions:- 
0.1 N HCl was prepared in 80% ethanol which was used to dissolve L-glutamic acid and L-
aspartic acid. 
Preparation of Stock Solution of L-Glutamic Acid and L-Aspartic Acid:- 
Stock solutions of L-glutamic acid and L-aspartic acid  were  prepared  by dissolving  
1mg,2mgand 4mg of the respective amino acid in  1mL  of   0.1 N HCl (1 mg/mL). 
Materials & methods  
 
Department of Pharmacology, PSGCOP Page 35 
Preparation of 0.2% Ninhydrin Solution:- 
In 100 mL standard ﬂask, 200 mg of ninhydrin was taken and dissolved in acetone. Then add  
1mL of pyridine and make up the volume with 100 mL acetone 
Preparation of Brain Tissue Samples:- 
 Rats were sacriﬁced under ether anesthesia and their brains was excised out quickly in ice cold 
conditions and stored at -80°C. The hippocampus region was homogenized in 0.1 N HCl (for 
every 10 mg tissue/200 mL) in a manual homogenizer. The homogenates were transferred to 
polypropylene tubes and centrifuged at 4500 rpm for 20 min at 25°C. The supernatant was then 
transferred into micro centrifuge tubes and used at the earliest for spot application.  
Procedure: 
A 5µL volume of the standard solutions of (L-glutamic acid, L-aspartic acid) and brain samples 
was applied on a prewashed (ethanol) HPTLC plate. Spots were dried in a hot air oven at 60–
65°C for 1–2 min and the plate was developed in the mobile phase n-butanol: glacial acetic acid: 
water (65:15:25). When the solvent front reached the top of the plate, the plates were removed 
and dried at 60–65°C for 3–4 min in a hot air oven.The plates were then dipped (1 sec) in 0.2% 
ninhydrin reagent and dried in a hot air oven at 60–65°C for 3–4 min. The spots were scanned at 
486 nm and the peak areas were recorded. Calibration curves of L-glutamic acid and L-aspartic 
acid were prepared by plotting areas vs. concentration (Babu et al., 2007). 
5.7. Histopathological Evaluation: 
The histopathological examination of the myelin sheath level in the sciatic nerve will be 
analyzed qualitatively for the extent of axonal degeneration. Samples of sciatic nerve will be 
stored in a fixative solution (10% formalin) and staining will be done by using hematoxylin and 
eosin as described by method of (Oznuret al.,2016). 
5.8. Statistical Analysis: 
Data were given in the form of arithmetical mean values and standard error mean of variance. 
Data’s of hot plate test, Randall Sellito test, electronic Von Frey test were subjected to Two way 
Materials & methods  
 
Department of Pharmacology, PSGCOP Page 36 
ANOVA followed by Bonferroni’s post hoc test for comparison. The data’s of formalin test and 
sciatic functional index were subjected to One way ANOVA (Analysis of variance) followed by 
post hoc Tukey’s multiple comparison test. The level of significance was accepted at p<0.05.The 
analysis was carried out by using Graph pad prism software of version 5.03. 
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6. RESULTS 
6.1. Effect of PM on hot plate test in vincristine induced neuropathic pain rat model  
Vincristine (75µg/kg) administration for ten days resulted in significant development of thermal 
hyperalgesia as reflected by increase in paw licking and jumping from the hot plate surface. The 
increased pain perception is the symptoms of neurotoxicity or neuropathic pain. Administration 
of PM attenuated vincristine induced decrease in the nociceptive threshold for thermal 
hyperalgesia .Control group showed significant difference in pain threshold on 12
th 
and 21
st
 day 
when compared to the other groups. F (6, 35) = 11.81, p<0.05[PM 200mg; post-admin, 12
th
 day], 
p<0.001[PM 200mg; co-admin, 12
th
 day] and p<0.001[vincristine 12
th
 & 21
st
 day, PM 100mg; 
post & co-admin 12
th
 & 21
st
 day, PM 200mg; co-admin 21
st
 day, pregabalin 21
st
 day]. It showed 
significant increase in pain threshold on 12
th 
and 21
st
 day when compared to the vincristine 
treated group (p<0.001). Vincristine treated group showed significant reduction in the pain 
threshold on 12
th 
and 21
st
 day when compared to the other groups  (F (6, 35) =11.81, p<0.001). 
Treatment with standard drug Pregabalin (10mg/kg)  showed significant increase in pain 
threshold on 12
th 
and 21
st
 day when compared to treatment with test drug PM post & co- 
administration (100mg/kg) F (6, 35) = 11.81,  p<0.01[PM 100mg; co-admin 21
st
 day], 
p<0.001[PM 100mg; post-admin 12
th 
& 21
st
 day]. Treatment with test drug PM post 
administration (100mg/kg) showed significant difference in pain threshold on 12
th
 and 21
st
 when 
compared to treatment with test drug PM post administration (200mg/kg) and co – 
administration (200mg/kg) F (6, 35) =11.81, p<0.05[PM 200mg; post-admin 21
st
 day], 
p<0.01[PM 200mg; co-admin 12
th
 & 21
st
 day] and p<0.001[PM 200mg; post-admin 12
th
 day]. 
Treatment with test drug PM post administration (200mg/kg) showed significant difference in 
pain threshold on 12
th 
and 21
st
 when compared to treatment with the test drug PM co-
administration (100mg/kg) F (6, 35) = 11.81, p< 0.05). 
6.2. Effect of PM on Randall Sellito test in vincristine induced neuropathic pain rat model  
Vincristine administered rats exhibited a significant development of mechanical hyperalgesia as 
reflected by either a flinch response or withdrawal of hind paw. Administration of PM attenuated 
vincristine induced decrease in the nociceptive threshold for mechanical hyperalgesia. Control 
group showed significant difference  in pain threshold on  12
th 
 and 21
st
 day  when compared to 
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the  vincristine treated group, treatment with the test drug PM post administration  (100mg/kg  & 
200mg/kg) F (6, 35) =13.16, p<0.05[PM 200mg; post-admin 12
th
 day] and p<0.001[vincristine, 
PM 100mg; post-admin 12
th
 & 21
st
 day]. Vincristine treated group showed significant reduction 
in the pain threshold on 12
th 
and 21
st
 day when compared to the other groups (F (6, 35) =13.16, 
p<0.001). Treatment with standard drug Pregabalin (10mg/kg) showed significant difference in 
pain threshold on 12
th 
and 21
st
 day when compared to treatment with test drug PM post & co- 
administration (100mg/kg and 200mg/kg) F (6, 35) =13.16, p<0.05[PM 200mg; co-admin 12
th
 & 
21
st
 day], p<0.01[PM 100mg; co-admin 12
th
 day], p<0.001[PM 100mg; co-admin 21
st
, PM 100& 
200mg; post-admin 12
th
 & 21
st
 day].Treatment with test drug PM post administration 
(100mg/kg) showed significant difference in pain threshold on  12
th 
and 21
st 
when compared to 
treatment  with test drug PM  co – administration (100mg/kg and 200mg/kg) F(6, 35) =13.16,  
p< 0.05[PM 100mg; co-admin 12
th
 day, PM 200mg; co-admin 21
st
 day], p< 0.01[PM 200mg; co-
admin 12
th
 day]. 
6.3 Effect of PM on electronic Von Frey test in vincristine induced neuropathic pain rat 
model  
Administration of Vincristine (75µg/kg) for ten days resulted in a significant development of 
mechanical allodynia as reflected by the significant increase in hind paw withdrawal reflux. 
Administration of PM attenuated vincristine induced decrease in the nociceptive threshold for 
mechanical allodynia. Control group showed significant difference in pain threshold on12
th
 and 
21
st
day in comparison to vincristine treated group and treatment with test drug PM post 
administration of 100mg/kg and 200mg/kg F (6, 35) =1.219 p<0.05[PM 200mg; post-admin 12
th
 
day], p<0.01[PM 100mg; post-admin 12
th
 day], p<0.001[vincristine 12
th
 & 21
st
 day]. Vincristine 
treated group showed significant reduction in the pain threshold on 12
th 
and 21
st
 day when 
compared to the other groups F (6, 35) =1.219, p<0.05[PM 100mg; post-admin 21
st
 day, PM 
200mg; co-admin 12
th
 day], p<0.01[PM 100mg; co-admin 21
st
 day, PM 200mg; post-admin 21
st
 
day] and p<0.001[PM 200mg; co-admin 21
st
 day]. 
6.4. Effect of PM on formalin test in vincristine induced neuropathic pain rat model  
The effect of PM in formalin test was measured in two different phases, acute and delayed phase 
based on paw licking and paw elevation parameters. 
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6.4.1. Effect of PM on acute phase (0-10mins) 
Paw licking 
Formalin injection in control group showed significant difference  in paw licking when 
compared to vincristine treated  group, treatment with test drug PM post and  co – administration 
(100mg/kg and 200mg/kg) F (6, 35) =82.93, p<0.01[PM 200mg; co-admin], p<0.001[vincristine; 
PM 100& 200mg; post-admin, PM 100mg; co-admin]. Vincristine treated group showed  
significant increase in paw  licking  when compared to treatment with standard drug Pregabalin 
(10mg/kg) as well as the test drug PM (100mg/kg and 200mg/kg) post and co-administration (F 
(6, 35) =82.93, p<0.001). Treatment with standard drug Pregabalin (10mg/kg) showed 
significant difference in paw licking when compared to treatment with test drug PM post and  co-
administration (100mg/kg  and 200mg/kg) (F (6, 35) =82.93, p<0.001).Treatment with test drug 
PM post administration (100mg/kg) showed significant difference  in paw licking when 
compared to treatment with test drug PM co-administration (100mg/kg and 200mg/kg) F (6, 35) 
=82.93, p<0.05[PM 100mg; co-admin], p<0.001[PM 200mg; co-admin].Treatment with test drug 
PM post administration (200mg/kg) showed significant difference  in paw licking when 
compared to treatment with test drug PM co-administration (200mg/kg) (F (6, 35) =82.93, 
p<0.01). 
Paw elevation  
Formalin injection in control group showed significant difference  in paw elevation when 
compared to vincristine treated  group, treatment with test drug PM post and  co – administration 
(100mg/kg and 200mg/kg) F (6, 35) =82.93, p<0.01[PM 200mg; co-admin], p<0.001[vincristine, 
PM 100 & 200mg; post-admin, PM 100mg; co-admin]. Vincristine treated group showed  
significant increase in paw elevation when compared to treatment with standard drug Pregabalin 
(10mg/kg) as well as the test drug PM (100mg/kg and 200mg/kg) post and co-administration (F 
(6, 35)  =82.93,  p<0.001). Treatment with standard drug Pregabalin (10mg/kg) showed 
significant difference in paw elevation when compared to treatment with test drug PM post and 
co-administration (100mg/kg and 200mg/kg) (F (6, 35) =82.93, p<0.001). Treatment with test 
drug PM post administration (100mg/kg) showed significant difference in paw elevation when 
compared to treatment with test drug PM co-administration (100mg/kg and 200mg/kg) F (6, 35) 
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=82.93, p<0.05[PM 100mg; co-admin], p<0.001[PM 200mg; co-admin]. Treatment with test 
drug PM post administration (200mg/kg) showed significant difference in paw elevation when 
compared to treatment with test drug PM co-administration (200mg/kg) (F (6, 35) =82.93, 
p<0.01). 
6.4.2. Effect of PM on delayed phase (20-40mins) 
Paw licking  
Formalin injection in control group showed significant difference  in paw licking when 
compared to vincristine treated  group, treatment with test drug PM post (100mg/kg and 
200mg/kg) and co–administration (100mg/kg)  F (6, 35) = 22.58, p<0.01[PM 100mg; co-admin], 
p<0.001[vincristine, PM 100 &200mg; post-admin]. Vincristine treated group showed  
significant increase in paw licking when compared to treatment with standard drug Pregabalin 
(10mg/kg) as well as the test drug PM (100mg/kg  and 200mg/kg) post and co-administration F 
(6, 35) =22.58, p<0.01[PM 100mg; post-admin], p<0.001[PM 200mg post-admin]. Treatment 
with standard drug Pregabalin (10mg/kg) showed significant difference in paw licking when 
compared to treatment with test drug PM post administration (100mg/kg  and 200mg/kg) F (6, 
35) =22.58, p<0.05[PM 200mg; post-admin], p<0.01[PM 100mg; post-admin].Treatment with 
test drug PM post administration (100mg/kg) showed significant difference in paw licking when 
compared to treatment with test drug PM co-administration (200mg/kg) (F (6, 35) =22.58, 
p<0.05). 
Paw elevation   
Formalin injection in control group showed significant difference in paw elevation when 
compared to vincristine treated  group, treatment with test drug PM post (100mg/kg and 
200mg/kg) and co –administration (100mg/kg) F (6, 35) = 22.58, p<0.01[PM 100mg; co-admin], 
p<0.001[vincristine PM 100& 200mg; post-admin]. Vincristine treated group showed  
significant increase in paw  elevation when compared to treatment with standard drug Pregabalin 
(10mg/kg) as well as the test drug PM (100mg/kg  and 200mg/kg) post and co-administration F 
(6, 35) =22.58, p<0.01[PM 100mg; post-admin], p<0.001[pregabalin, PM 100mg; co-admin, PM 
200mg; post & co-admin]. Treatment with standard drug Pregabalin (10mg/kg) showed 
significant difference in paw elevation when compared to treatment with test drug PM post 
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administration (100mg/kg and 200mg/kg) F (6, 35) =22.58, p<0.05[PM 200mg; post-admin], 
p<0.01[PM 100mg; post-admin]. Treatment with test drug PM post administration (100mg/kg) 
showed significant difference in paw elevation when compared to treatment with test drug PM 
co-administration (200mg/kg) (F (6, 35) =22.58, p<0.05). 
6.5. Effect of PM on sciatic functional index in vincristine induced neuropathic pain rat 
model  
Vincristine (75µg/kg) administration for ten days resulted in significant sciatic functional loss 
and administration of PM significantly attenuated the vincristine induced rise in sciatic 
functional index. Control group showed significant difference in sciatic functional index level 
when compared to vincristine treated group. Treatment with standard drug Pregabalin 
(10mg/kg)as well as the test drug PM (100mg/kg & 200mg/kg) post and treatment with co – 
administration (F (6, 35) =1304, p<0.001). Vincristine administered rats resulted in sciatic 
functional loss as reflected  by a  significant rise in sciatic functional index level when compared 
to treatment with  standard drug Pregabalin (10mg/kg) as well as the test drug PM (100mg/kg & 
200mg/kg)  post and  with co–administration (F (6, 35) =1304, p<0.001).Treatment with  
Standard drug Pregabalin (10mg/kg)  showed significant difference in sciatic functional index 
level  when compared to treatment with the test drug  PM (100mg/kg & 200mg/kg) post and co-
administration (F (6, 35) =1304, p<0.001). Treatment with the test drug PM post administration 
(100mg/kg) showed significant difference in sciatic functional index level when compared to 
treatment with the test drug PM post (200mg/kg) and co-administration (100mg/kg & 200mg/kg) 
(F (6, 35) =1304, p<0.001). Treatment with the test drug PM post administration (200mg/kg) 
showed significant difference in sciatic functional index level when compared to treatment with 
the test drug PM co-administration (100mg/kg & 200mg/kg) (F (6, 35) =1304, p< 0.001). 
6.6. Effect of PM on excitatory neurotransmitters in rat brain 
6.6.1. HPTLC fingerprinting 
Finger printing of reference standards such as glutamate and aspartate along with brain samples 
was done using   HPTLC and the spots were visualized at 486 nm. The solvent system used for 
the development of chromatogram was n-butanol, glacial acetic acid, water (65:15:25)v/v/v).The 
pink colour spots obtained on the chromatogram after spraying of ninhydrin indicated the 
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presence of glutamate and aspartate in the brain samples. A defined peak at Rf between 0.40 and 
0.60 were obtained for standard glutamate and aspartate. The 3D display of the densitogram at 
486nm and chromatogram indicated the presence of glutamate and aspartate in the brain samples. 
6.6.2. Effect of PM on glutamate levels in vincristine induced neuropathic pain rat model  
The concentration obtained from HPTLC was analysed by One way ANOVA followed by 
Tukey’s multiple comparison test. Data’s were expressed in ng/mg of wet tissue. It was found 
that PM significantly attenuated vincristine induced rise in glutamate levels. Control group 
showed significant difference in glutamate levels when compared to vincristine treated group. 
Treatment with standard drug Pregabalin (10mg/kg) as well as the test drug PM (100mg/kg & 
200mg/kg) post and treatment with co – administration (F (6, 35) = 664.4, p<0.001). Vincristine 
administered rats resulted in  significant rise in glutamate  level when compared to treatment 
with  standard drug Pregabalin (10mg/kg) as well as the test drug PM(100mg/kg & 200mg/kg) 
post and  co – administration (F ( 6, 35) = 664.4, p< 0.05,  p<0.001).Treatment with  Standard 
drug Pregabalin (10mg/kg)  showed significant difference in glutamate level when compared to 
treatment with the test drug PM (100mg/kg & 200mg/kg) post and co-administration (F (6, 35) = 
664.4, p<0.05, p<0.001). Treatment with the test drug PM post administration (100mg/kg) 
showed significant difference in glutamate level when compared to treatment with the test drug 
PMpost (200mg/kg) and co-administration (100mg/kg & 200mg/kg) (F (6, 35) =664.4, p<0.001). 
Treatment with the test drug PM post administration (200mg/kg) showed significant difference 
in glutamate level when compared to treatment with the test drug PM co-administration 
(100mg/kg & 200mg/kg) (F (6, 35) =664.4, p<0.001). 
6.6.3. Effect of PM on aspartate levels in vincristine induced neuropathic pain rat model  
The concentration obtained from HPTLC was analysed by One way ANOVA followed by 
Tukey’s multiple comparison test. Data’s were expressed in ng/mg of wet tissue. It was found 
that PM significantly attenuated vincristine induced rise in aspartate levels. Control group 
showed significant difference in aspartate levels when compared to vincristine treated group. 
Treatment with the test drug PM (100mg/kg & 200mg/kg) post and treatment with co– 
administration (F (6, 35) =141.8, p<0.001). Vincristine administered rats resulted in  significant 
rise in aspartate level when compared to treatment with  standard drug Pregabalin (10mg/kg) as 
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well as the test drug PM post (200mg/kg) and  with co – administration (100mg/kg & 200mg/kg) 
(F (6, 35) =141.8,  p<0.001).Treatment with Standard drug Pregabalin (10mg/kg) showed 
significant difference in aspartate level when compared to treatment with the test drug  
PM(100mg/kg & 200mg/kg) post and co-administration (F (6, 35) =141.8, p< 0.05,  p<0.001). 
Treatment with  the test drug  PM post administration (100mg/kg) showed significant difference 
in aspartate  level  when compared to treatment with the test drug  PM post (200mg/kg) and co-
administration(100mg/kg & 200mg/kg)  (F (6,35)=141.8, p<0.001). Treatment with the test drug 
PM post administration (200mg/kg) showed significant difference in aspartate level when 
compared to treatment with the test drug PM co-administration (200mg/kg) (F (6, 35) =141.8, 
p<0.001). Treatment with the test drug PM co-administration (200mg/kg) showed significant 
difference in aspartate level when compared to treatment with the test drug PM co-administration 
(200mg/kg) (F (6, 35) =141.8, p<0.05). 
6.7. Histopathology  
Vincristine treated  group resulted in significant histopathological changes when compared to the 
other groups  such as axonal degeneration, schwann cell hyperplasia,  damage of myelin sheath, 
fibrosis which were assessed in the  transverse sections of sciatic nerve. Treatment with standard 
drug Pregabalin (10mg/kg) as well the test drug PM (100mg/kg & 200mg/kg) post and co-
administration significantly attenuated vincristine induced axonal degeneration (caused axonal 
regeneration) and other histopathological changes. 
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Fig: 6. Effect of PM on hot plate test in vincristine model 
 
All the data’s are expressed as mean ± SD n=6 rats per group. Two way ANOVA followed by 
Bonferonni’s post hoc- test.  a, b and c denotes statistical significance at  p<0.05, p<0.01  and  
p<0.001  respectively in comparison to the control group. zdenotes statistical significance at 
p<0.001  in comparison to the vincristine treated group. l , m denotes statistical significance at  
p<0.01  and  p<0.001  respectively in comparison to the treatment with  standard Pregabalin  
group. p ,q ,r denotes statistical significance at p <0.05, p<0.01  and p<0.001   respectively  in 
comparison to the  treatment with test drug PM post administration group(100mg/kg).d  denotes 
statistical significance at p <0.05 in comparison treatment with test drug PM to the  post 
administration group(200mg/kg). 
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Fig: 7. Effect of PM on Randall Sellito test in vincristine model 
 
All the data’s are expressed as mean ± SD n=6 rats per group. Two way ANOVA followed by 
Bonferonni’s post hoc- test. a, c denotes statistical significance at p<0.05, p<0.001 in 
comparison to the control group. zdenotes statistical significance at p < 0.001  in comparison to 
the vincristine treated group. k, l , m denotes statistical significance at  p <0.05   p < 0.01  and  p 
< 0.001  respectively in comparison to the treatment with  standard  drug Pregabalin  group. p ,q 
denotes statistical significance at p < 0.05  and  p < 0.01   respectively  in comparison to the 
treatment with test drug PM post administration group(100mg/kg). 
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Fig: 8. Effect of PM on electronic Von Frey test in vincristine model  
 
All the data’s are expressed as mean ± SD n=6 rats per group. Two way ANOVA followed by 
Bonferonni’s post hoc- test. a, b, c denotes statistical significance at p<0.05, p<0.01, p<0.001   in 
comparison to the control group. x, y, z  denotes statistical significance at  p<0.05,  p< 0.01 and  
p<0.001  in comparison to the vincristine treated group.  
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Fig: 9. Effect of PM on formalin test in vincristine model (acute phase) 
 
All the data’s are expressed as mean ± SD n=6 rats per group.One way ANOVA followed by 
post hoc Tukey’s multiple comparison test. b, c denotes statistical significance at p<0.01, 
p<0.001 in comparison to the control group.  z denotes statistical significance at  p<0.001 in 
comparison to the vincristine treated group.  m denotes statistical significance at p< 0.001  
respectively in comparison to the treatment with  standard  drug Pregabalin  group. p, r denotes 
statistical significance at p<0.05 and p<0.001 respectively  in comparison to the treatment with 
test drug PM post administration group (100mg/kg). e denotes statistical significance at  p<0.01  
comparison to the treatment with test drug PM post administration group (200mg/kg). 
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Fig: 10. Effect of PM on formalin test in vincristine model (delayed phase) 
All the data’s are expressed as mean ± SD n=6 rats per group. One way ANOVA followed by 
post hoc Tukey’s multiple comparison test. b, c denotes statistical significance at p<0.01, 
p<0.001   in comparison to the control group.  y, z  denotes statistical significance at p<0.01, 
p<0.001  in comparison to the vincristine treated group.  k, l denotes statistical significance at 
p<0.05 and p<0.01 respectively in comparison to the treatment with  standard  drug Pregabalin  
group. r denotes statistical significance at p<0.001 in comparison to the treatment with test drug 
PM post administration group (100mg/kg). 
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Fig: 11. Effect of PM on sciatic functional index in vincristine model  
 
All the data’s are expressed as mean ± SD n=6 rats per group. One way ANOVA followed by 
post hoc Tukey’s multiple comparison test.c denotes statistical significance at p < 0.001   in 
comparison to the control group.   z denotes statistical significance at  p< 0.001  in comparison to 
the vincristine treated group. m denotes statistical significance at p < 0.001  in comparison to the 
treatment with  standard  drug Pregabalin  group. r denotes statistical significance at   p < 0.001    
in comparison to the treatment with test drug PM post administration group(100mg/kg).f denotes 
statistical significance at   p < 0.001   in comparison to the treatment with test drug PM post 
administration group(200mg/kg). v denotes statistical significance at   p < 0.001   respectively  in 
comparison to the treatment with test drug PM co-administration group(100mg/kg). 
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Effect of PM on excitatory neurotransmitters in rat brain 
Fig: 12. 3D Value of glutamate and aspartate
 
Fig: 13. Chromatogram for standard Glutamate 
 
Fig: 14. Chromatogram for standard Aspartate 
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Fig: 15. Chromatogram for Glutamate in different groups 
   
 
 
 
 
 
 
 
 
 
 
 
 
Control  Vin+saline(75µg/kg) 
Vin +Pregabalin(10mg/kg) 
Vin+PM(100mg//kg)(co-admin) 
Vin+PM(200mg//kg)(co-admin) 
Vin+PM(100mg/kg) (post admin) 
Vin+PM(200mg/kg) (post admin) 
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Fig: 16. Chromatogram for Aspartate in different groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control  Vin+saline(75µg/kg) 
Vin +Pregabalin(10mg/kg) 
Vin+PM(100mg//kg)(co-admin) 
Vin+PM(200mg/kg)(co-admin) 
Vin+PM(100mg/kg) (post admin) 
Vin+PM(200mg/kg) (post admin) 
Results 
 
Department of Pharmacology, PSGCOP Page 53 
 
Table: 4. Effect of PM on Glutamate levels in vincristine model 
 
Sl. No Treatment Conc (ng/mg of wet tissue) 
1. Control (saline) 173.687 
2. Vincristine +saline(75µg/kg) 551.186 
3. Vincristine +Pregabalin(10mg/kg) 213.776 
4. Vincristine +PM(100mg/kg) (post admin) 394.770 
5. Vincristine +PM(200mg/kg) (post admin) 303.497 
6. Vincristine +PM(100mg//kg) (co-admin) 261.977 
7. Vincristine +PM(200mg//kg) (co-admin) 231.434 
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Fig: 17. Effect of PM on Glutamate levels in vincristine model 
 
All the data’s are expressed as mean ± SD n=6 rats per group. One way ANOVA followed by 
post hoc Tukey’s multiple comparison test.c denotes statistical significance at p < 0.001   in 
comparison to the control group.   z denotes statistical significance at  p< 0.001  in comparison to 
the vincristine treated group. k,m denotes statistical significance at   p < 0.05   ,  p < 0.001  in 
comparison to the treatment with  standard  drug Pregabalin  group. r denotes statistical 
significance at   p < 0.001    in comparison to the treatment with test drug PM post administration 
group(100mg/kg).f denotes statistical significance at   p < 0.001   in comparison to the treatment 
with test drug PM post administration group(200mg/kg).  
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Table: 5. Effect of PM on Aspartate levels in vincristine model 
Sl.no Treatment Conc (ng/mg of wet tissue) 
1. Control (saline) 34.571 
2. Vincristine +saline(75µg/kg) 191.337 
3. Vincristine +Pregabalin(10mg/kg) 46.588 
4. Vincristine +PM(100mg/kg) (post admin) 171.859 
5. Vincristine +PM(200mg/kg) (post admin) 121.358 
6. Vincristine +PM(100mg//kg) (co-admin) 95.911 
7. Vincristine +PM(200mg//kg) s(co-admin) 70.700 
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Fig: 18. Effect of PM on Aspartate levels in vincristine model 
 
All the data’s are expressed as mean ± SD n=6 rats per group. One way ANOVA followed by 
post hoc Tukey’s multiple comparison test.c denotes statistical significance at p < 0.001   in 
comparison to the control group.   z denotes statistical significance at  p< 0.001  in comparison to 
the vincristine treated group. k,m denotes statistical significance at p<0.05, p<0.001 in 
comparison to the treatment with standard drug Pregabalin group. r denotes statistical 
significance at   p < 0.001    in comparison to the treatment with test drug PM post administration 
group(100mg/kg).f denotes statistical significance at   p < 0.001   in comparison to the treatment 
with test drug PM post administration group(200mg/kg). t denotes statistical significance at   
p<0.05  in comparison to the treatment with test drug PM co-administration group(100mg/kg). 
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Fig: 19. Histopathology of sciatic nerve 
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7. DISCUSSION 
In the present study, we investigated the neuroprotective effect of Pterocarpus marsupium(PM) 
marketed capsules(100mg/kg & 200mg/kg) post and co–administration against vincristine(VCR) 
induced neuropathy. As demonstrated earlier, (Balaji et al., 2015, Muthuraman  et 
al.,2011,2008) vincristine injected rats (75µg/ kg ,i.p for 10 days) exhibited peripheral 
neuropathy  which was evident from the significant decrease in nociceptive threshold in  
behavioural models such as thermal  hyperalgesia, mechanical  hyperalgesia, mechanical 
allodynia. It increased the paw licking and paw elevation response in formalin test and also 
caused sciatic functional loss. It was also observed that there was neurochemical(rise in 
excitatory neurotransmitters such as glutamate and aspartate levels) and histopathological 
changes(axonal degeneration) due to vincristine administration. The behavioural, neurochemical 
and histopathological alterations caused by vincristine may be linked to itsneurotoxic effects in 
which they act directly or indirectly on the sensory neurons and causes a reduction in amplitude 
of action potential,slow conduction velocity and thereby inducing pain(Jain et 
al.,2012).Administration of Pterocarpus marsupium marketed capsules ameliorated vincristine 
induced behavioural, neurochemical and histopathological changes. These effects of PM may be 
due to its anti-inflammatory, anti –oxidative, analgesic activity which is in line with the previous 
studies. (Pant DR et al., 2017). 
 
Vincristine has been widely employed as a chemotherapeutic agent for the management of 
various cancers including Hodgkin's disease (Villani F et al., 2008).However, its clinical 
application has been limited due to unavoidable painful peripheral neuropathy Effective 
management of  chemotherapy induced peripheral neuropathy (CIPN) in the clinical setting has 
been an important and challenging  goal to achieve. Systemic treatment with vincristine damages 
Schwann cells and DRG neurons. (Kiguchi N et al., 2009).The molecular mechanism behind 
vincristine induced neurotoxicity was found to involve high cellular calcium levels, free radical 
generation, TNF-alpha expression, and MPO activation (Jaggi et al., 2012, Kesik V et al., 
2010).These events are responsible for axonal degeneration, indicating that cellular oxidant and 
inflammatory mediators play a key role in the pathogenesis of painful neuropathy. Earlier reports 
suggest that neuropathic pain has been linked with rise in neuronal calcium levels followed by 
enhance in the oxidative stress markers (free radicals) and inflammatory cytokines IL-6, etc. 
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(Jain V  et al., 2009, Thiagarajan VR  et al., 2014).Other possible mechanismsbehind vincristine 
induced neuropathy are mitochondrial changes (Broyl A et al., 2010), increase in sodium ion 
current in DRG predisposing to paraesthesia and fasciculations (Ghelardini C et al., 2010), 
activation of calcium activated proteases calpains and caspases in DRG neurons (JosephEK et 
al., 2004) increase in 5-HT2A receptors on dorsal horn and DRG neurons (Thibault K et al., 
2008) and dysfunction of the spinal NO/cGMP pathway (Kamei J et al., 2005). 
 
Thermal hyperalgesia (hot plate test) and mechanical hyperalgesia (Randall Sellito test) 
associated with vincristine treatment were thought to occur due to the hyper responsiveness of 
the degenerated Aδ and C-myelinated fibres (Dougherty et al., 2007; Xiao and Bennett, 2008). 
Spontaneous discharges and abnormal ‘wind-up’ to electrical stimuli in spinal cord neurons 
suggest a central sensitization after repeated vincristine treatment that may contribute to the 
spontaneous pain and hyperalgesia (Wenget al., 2003).In accordance with the previous findings, 
thermal and mechanical hypersensitivity can occur due to the increased expression of 5-
hydroxytryptamine (5-HT) receptor 5-HT2Ain the dorsal horn after vincristine treatment. 
(Hibaultk et al., 2008) (Hansen, N et al., 2011). In addition, vincristine treatment increases the 
activity of T-type calcium channels and TRPV4 in sensory neurons of the DRG (Flatters et al., 
2004) (Alessandri-Haber et al., 2004). As per the previous studies it was found that mechanical 
hyperalgesia and allodynia (electronic Von Frey test) can occur due to the increased expression 
of TRPV1 in the rat DRG (Terumasa Chiba et al., 2017). Mechanical allodynia is mainly caused 
due to the hyperresposiveness of the Aβ fibres  (Thibault K et al., 2008) and  a research report 
suggested that IL-6 may stimulate the invasion of macrophages in the peripheral nervous system 
and elicit VCR-induced mechanical allodynia (Gong SS et al ., 2016). According to the previous 
studies spinal microglia and astrocytes respond to vincristine induced peripheral neuropathy. 
Numerous laboratories have highlighted the importance of central glial activation in the 
development of hyperalgesia and allodynia in both peripheral inflammatory as well as in 
vincristine induced neuropathic pain model (J. Mika et al., 2013). These activated glial cells 
upregulate and secrete pronociceptive substances such as NO, prostaglandins and pro-
inflammatory interleukins and TNF-α. Hence, any agent which can attenuate pro-nociceptive 
substances and pro-inflammatory mediators have been successful in attenuating neuropathic pain 
(V.A. Carozzi et al., 2014) (M. Sisignano et al., 2014). In this line, the analgesic and anti-
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inflammatory effect observed by PM (100mg/kg & 200mg/kg) post and co–administration 
treatment in vincristine induced peripheral neuropathy can be justified. 
 
P. marsupium showed potential analgesicand anti-inflammatory activity which is in agreement 
with the previous studies. These effects may be due to the presence of   phytochemicals such as 
alkaloids, coumarins, flavonoids, glycosides, terpenoids, tannins, phenols, saponins, and steroids 
in the drug (Pant et al., 2017, Mohammed RM et al., 2012, Sikdar A et al., 2013). It was reported 
that α-DHC isolated from the heartwood of P. marsupium is responsible for its anti-
inflammatory activity.The anti-inflammatory activity is exerted by two ways a) by down-
regulating MAPKs and restricting nuclear stabilization of NF-κB that ultimately inhibits the over 
expression of pro-inflammatory cytokines as well as inflammation mediating enzymes b) by 
disrupting Nrf-2–Keap-1 complex leading to induction of cytoprotective enzymes that indirectly 
repress the expression of inflammatory mediators (Chakraborty P et al., 2015).The anti-
inflammatory and analgesic activity of the drug can also be linked to the PGE2 inhibitory activity 
of the drug. This inhibitory activity of the drug is due to the presence of pterostilbene   which 
exhibits a COX -2 inhibitory activity (Hougee Set al., 2005). In accordance with the previous 
studies PM  decreased the  elevated inflammatory cytokine, tumor necrosis factor (TNF-α) in 
type 2 diabetic rats which can also be taken into consideration  for its anti-inflammatory activity 
(Kiranahalagappa et al., 2010).The activity of PM in vincristine  induced peripheral neuropathy 
can also be linked to its anti-oxidant activity. Previous studies have reported the anti-oxidant 
activity of the drug (Mahnaaz Mohammadi et al., 2009). 
 
The nociception induced by formalin is associated with injured tissue. It has been reported that 
this nociception resembles more closely the clinical pain in comparison to other tests that induce 
pain by mechanical or thermal stimuli (Lopes et al., 2009). Formalin test is characterized by two 
phases: acute and delayed. The acute phase (0-10 mins) is short-lived and initiates immediately 
after injection and is characterized by C-fiber activation due to peripheral stimuli. The delayed 
phase (20-40 mins) is a longer, persistent period caused by local tissue inflammation and also by 
functional changes in the dorsal horn of the spinal cord. Therefore this phase is inhibited both by 
opioids and analgesic agents. Substances that act primarily as central analgesics inhibit both 
phases while peripherally acting drugs inhibit only the delayed phase (Le bars et al., 2001). 
According to the present study it was found that PM decreased the pain responses such as paw 
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licking and paw elevation in acute and delayed phase of formalin test.This suggests that PM may 
be involved in both central and peripheral analgesic mechanisms as it inhibited both the acute 
and delayed phase in formalin test. 
SFI is an assessment of functional loss using three variables that measure print length, 
intermediatory toe spread and total toe spread. Thus SFI provides a noninvasive and quantitative 
method to evaluate functional recovery of walking ability, the ultimate goal is the regeneration of 
injured sciatic nerve (A.S. Varejao et al., 2004.) It was found that PM improved the sciatic 
functional loss caused by VCR and this may be due to the neuroprotective effect of the drug. 
 
Neuropathic pain caused by diabetic neuropathy and nerve injury is associated with increased 
glutamaterelease from primary afferent terminals and stimulation of AMPA receptors and 
metabotropic glutamate receptors, especially mGluR5, in the spinal cord (Hong-Yi Zhou et al., 
2011). Glutamate signaling is also altered in CIPN. Although glutamate mainly acts on 
postsynaptic receptors to mediate excitatory neurotransmission, presynaptic NMDARs can 
increase the release of neurotransmitters such as substance P from the primary afferent terminals 
in the spinal dorsal horn. Increased N-methyl-D-aspartate receptor (NMDAR) activity 
contributes to central sensitization in certain types of neuropathic pain. 
 
In the present study it was found that PM decreased the level of excitatory neurotransmitters 
such as glutamate and aspartate .The mechanism is still unclear, further investigation has to be 
done regarding this. VCR treatment caused axonal degeneration, schwann cell hyperplasia, 
damage of myelin fibrosis. This observation was in line with the previous studies (Wolfgang 
Boehmerle et al., 2014). It was found that PM reversed the histopathological changes caused by 
VCR.This may be due to the potential neuroprotective effect of the drug. 
 
PM post and co-administration showed comparable results to standard Pregabalin (10mg/kg) in    
various behavioral models,biochemical estimation as well as histopathological studies. 
Pregabalin (10mg/kg) is a well-known agent currently used clinically to manage neuropathic 
pain of various etiologies (Navarro et al., 2011; Plested et al., 2010; Pérez et al., 2010). 
Although pregabalin mediated beneficial effects are proposed to be potentially mediated via 
inhibition of voltage gated calcium channels. In addition pregabalin has also been shown to 
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possesses good anti-oxidative, anti-TNF-alpha as well as anti-inflammatory actions (Ha et al., 
2011, 2008, Muthuramanand Singh et al., 2011,Beyreuther et al., 2007). 
Thus based on the behavioral,biochemical as well as histopathologoical results it can be 
concluded that Pterocarpus marsupium marketed capsules   (100mg/kg & 200mg/kg) post and 
co-administration) exerts a beneficial effect in vincristine induced neuropathic pain and thus it 
can be used as a neuroprotective agent. 
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8. SUMMARY   AND   CONCLUSION 
 
In our present study, we evaluated the anti-nociceptive effect of Pterocarpus marsupium 
marketed capsules (100mg/kg & 200mg/kg) post and co–administration against vincristine 
induced neuropathy in rat model. 
• Pterocarpus marsupium capsules (100mg/kg & 200mg/kg) post and co–administration 
showed significant increase in pain threshold in thermal hyperalgesia (hot plate test), 
mechanical hyperalgesia (Randall Sellito test), mechanical allodynia (electronic Von Frey 
test). 
• Neuropathic pain was induced by vincristine (75µg/kg) and the pain threshold was 
assessed by various behavioral studies. Vincristine caused a rise in the level of excitatory 
neurotransmitters such as glutamate and aspartate. 
• PM exhibited both central and peripheral actions in nociception as it decreased the paw 
licking and elevation in both acute and delayed phase of formalin test. 
• It attenuated the sciatic functional loss caused by vincristine. 
• PM decreased the levels of excitatory neurotransmitters such as glutamate and aspartate 
in the brain. 
• Histopathology of sciatic nerve also supported   the neuroprotective activity of the drug 
as it caused axonal regeneration and reversed the histopathological changes caused by 
vincristine. 
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CONCLUSION 
 
 
The study can be concluded that PM attenuated VCR induced behavioral, biochemical and 
histopatholological changes in rats. These effects of   PM may be attributed to different actions 
which include anti-nociceptve, anti-inflammatory, neuroprotective and anti- oxidant activity. 
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